
    
      The investigators are conducting a phase I/II study to determine the maximum-tolerated dose,
      the recommended dose, and to evaluate the response rate and toxicity of the TS-1, irinotecan
      and cisplatin combination in patients with advanced or metastatic NSCLC.
    
  